The proper response to the upjacking of the price of the EpiPen, courtesy of the FDA:
US regulators have approved new competition for EpiPen, the emergency allergy medicine that made Mylan a poster child for pharmaceutical company greed.
The Food and Drug Administration on Thursday approved Adamis Pharmaceuticals Corp.’s product, which should go on sale later this year.
Symjepi is a syringe prefilled with the hormone epinephrine, which helps stop life-threatening allergic reactions from insect stings and bites, foods such as nuts and eggs, or certain medications.
San Diego-based Adamis says its product is easier to use than Mylan’s EpiPen, a spring-loaded syringe filled with a set dose that comes with a training device.
Symjepi also is smaller than EpiPen, so it’s easier to fit in a pocket or purse.
Yes, but is it kinder to your wallet?
Adamis said it is still lining up a distributor so it hasn’t set the exact price for its product, which will be sold in pairs like EpiPen.
Adamis spokesman Mark Flather said Symjepi is intended to be a “low-cost alternative” to EpiPen and similar products, and the company is aiming to sell it for less than generic EpiPens.
We’ll have to keep an eye out for it.